CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Antibody-Rich Plasma from COVID-19 recovered patientsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Plasma Rich Antibodies From Recovered Patients From COVID19

Prospective interventional study, single arm of purified convalescent plasma transfusion as an add on therapy for the standard of care treatment (national guideline) (Oseltamivir (75mg/12 hours for 5-10 days) and hydroxychroquine (400mg twice in first day, 200 twice for 4-9 days) ± Azithromycin 500mg daily for 5 days

NCT04348877 Coronavirus Disease (COVID-19) Other: Antibody-Rich Plasma from COVID-19 recovered patients
MeSH:Coronavirus Infections

Primary Outcomes

Description: Two successive negative COVID-19 PCR analysis tests 72 hours apart

Measure: viral COVID-19 clearance

Time: 14 days

Secondary Outcomes

Description: The percentage of decrease of radiological abnormalities at day 14

Measure: Decrease of radiological abnormalities

Time: 14 days

Description: Clinical improvement in form of normal body temperature for 48 hours

Measure: Clinical improvement

Time: 14 days


No related HPO nodes (Using clinical trials)